Jiangbo Pharmaceuticals (ehem. GNPH) - A0RNJB/JGBO
http://www.jiangbopharma.com/
http://www.jiangbo.cn/
SEC-FILINGS:
http://www.sec.gov/cgi-bin/...amp;owner=include&action=getcompany
Kurs-Übersicht:
DTL - http://www.ariva.de/quote/simple.m?secu=102047202
USA - http://www.ariva.de/quote/simple.m?secu=102043409 &
http://ih.advfn.com/p.php?pid=squote&symbol=JGBO
Finanznachrichten/NEWS:
http://www.jiangbopharma.com/news.php?fir_lineid=79
http://www.finanznachrichten.de/...en/jiangbo-pharmaceuticals-inc.asp
http://finance.yahoo.com/q?s=JGBO.OB
Ami-Board:
http://investorshub.advfn.com/boards/board.aspx?board_id=743
ehemaliger GNPH-Thread (Ariva):
http://www.ariva.de/...harmaceuticals_Enterprises_t344223#jump5849073
**************************************************
23.04.2009
http://www.finanznachrichten.de/...-to-reflect-its-brand-name-008.htm
Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
LAIYANG, China, April 23 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, (News) Inc. (BULLETIN BOARD: GNPH) (the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has changed its name to "Jiangbo Pharmaceuticals, Inc." ("Jiangbo").
...(weiter siehe LINK)
24.04.2009
http://www.jiangbopharma.com/...&fir_lineid=79&sec_lineid=490
...
OTCBB-listed Jiangbo Pharma is also currently preparing to list on the Nasdaq within the next six to 12 months, Sung said.
13.05.2009
http://www.finanznachrichten.de/...erse-aenderung-change-isin-029.htm
CHANGE: ISIN
US37184Q2012 GNY1 GENESIS PHARMA.NEW DL-,02 13.05.2009
US47737R1014 GNY1 JIANGBO PHARMAC. DL-,02 14.05.2009
Tausch 1:1
Angehängte Grafik:
jiangbo.jpg (verkleinert auf 51%)
jiangbo.jpg (verkleinert auf 51%)
u.a.:
The total shares outstanding at May 13, 2009 were 10,351,448
As a result of the Corporate Name Change, our stock symbol changed to "JGBO" with the opening of trading on May 12, 2009 on the OTCBB.
REVENUES.
During the nine months ended March 31, 2009, we had revenues of $86.2 million as compared to revenues of $71.3 million for the nine months ended March 31, 2008, an increase of $15.0 million or approximately 21.0%.
Our revenues include sales to related parties of $0.2 million for the nine months ended March 31, 2009, as compared to $4.6 million for the nine months ended March 31, 2008, a decrease of $4.4 million or approximately 94.7%.
For the three months ended March 31, 2009, we had revenues of $25.7 million as compared to revenues of $26.2 million for the three months ended March 31, 2008, a decrease of $0.5 million or 1.9%.
For the three months ended March 31, 2009, we did not have any revenues from related party as compared to $1.9 million for the three months ended March 31, 2008, a decrease of $1.9 million or 100%.
While the quantities sold for Clarithromycin Sustained-released Tablets and Baobaole chewable tables increased in the three months ended March 31, 2009 as compared to the three months ended March 31, 2008, the decrease in the total revenue was primarily attributable to the decrease of the per unit price by average of 26% for Clarithromycin Sustained-released tablets, Itopride Hydrochloride granules and Baobaole chewable tables, beginning in January 2009.
The three products accounted for approximately 88.6 % of our total revenue for the three months ended March 31, 2009.
In January 2009 ,we restructured our distribution and sales system to sell our products primarily through 28 large independent regional distributors and lowered the per unit prices of the three major products to the distributors; at the same time, we reduce the commission paid to our sales representatives on those products to approximately 5%.
The decrease in the revenue generated from the three major products were partially offset by the increase in revenue from Radix Isatidis Dispersible tablets and other products we acquired in the Hongrui acquisition in January 2009.
The increase in revenue for the nine months ended March 31, 2009 as compared to the nine months ended March 31, 2008 was primarily due to the increase in sales volume of Baobaole chewable tables and the new product, Radix Isatidis Dispersible Tablets released in the second quarter of fiscal year 2009.
We believe that our product sales quantity will continue to grow in remainder of fiscal year 2009 as the market demand for our major products continues to be strong and we have recently launched three products, Yi Mu Cao Gao (a motherwort herb electuary sticky syrup), Gan Mao Zhi Ke Ke Li (an antipyretic and antitussive granule), and Kang Gu Sui Yan Pian (an osteomyelitis treatment tablet) that we acquired from Hongrui under our own brand name.
Jiangbo Pharmaceuticals, Inc. to Present at CCG IR's China Rising Conference in New York
On Tuesday May 12, 2009, 8:00 am EDT
LAIYANG, China, May 12 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; "Jiangbo" or the "Company") (which recently changed its name from Genesis Pharmaceuticals Enterprises, Inc.; OTC Bulletin Board: GNPH), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced today that its management will present at the upcoming China Rising Conference hosted by CCG Investor Relations in New York, NY on May 18, 2009.
The date, time and location of Jiangbo Pharmaceuticals, Inc. presentation at the China Rising Conference are:
Date: Monday, May 18, 2009
Time: 9:30 a.m. to 10:00 a.m. Eastern Time
Presenter: Ms Elsa Sung, Chief Financial Officer
Venue: The Yale Club
50 Vanderbilt Avenue
New York, NY 10017
Webcast: http://www.chinarisingconference.com/webcast.html
A replay of the webcast will be available for up to one year following the presentation using the same link.
The China Rising Investment Conference is hosted by CCG Investor Relations and will provide over 250 fund managers and investors access to senior management from a wide range of Chinese growth companies in sectors including consumer staples, agriculture, pharmaceuticals, infrastructure, information technology, advanced materials, capital goods, and alternative energy. The conference will include over 30 US-listed Chinese companies and a number of private companies.
Interested parties and investors can find more information for the conference by visiting CCG's China Rising conference website at: http://www.chinarisingconference.com .
JIANGBO HIIIIGH !!! ;-)
P.S. Poste mal Link zum 10Q bitte im PLI Board ... TY !! :-)
13.05.2009 21:53
Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
LAIYANG, China, May 13 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; "Jiangbo" or the "Company") (which recently changed its name from Genesis Pharmaceuticals Enterprises, (News) Inc., OTC Bulletin Board: GNPH), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 9:30 a.m. Eastern on Tuesday, May 19, 2009 to discuss financial results for the third quarter ended March 31, 2009 of its fiscal year 2009.
Conference Call
The conference call will include Mr. Wubo Cao, Chairman and CEO, Mr. Haibo Xu, COO, and Ms. Elsa Sung, CFO, of Jiangbo Pharmaceuticals.
To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (888) 481-7939. International callers should call (617) 847-8707. The Conference Passcode is 564 145 01.
If you are unable to participate in the call at that time, replay of the conference call will be available from Tuesday, May 19, 2009 at 11:30 a.m. Eastern for fourteen days. To access the replay, call (888) 286-8010. International callers should call (617) 801-6888. The Conference Replay Passcode is 547 268 69.
...(weiter siehe LINK)
ADVISORY, May 15, 2009 (GLOBE NEWSWIRE) --
What:
Representatives from Chinese companies will visit the NASDAQ
MarketSite in New York City's Times Square to mark the China Rising
Investment Conference at the Yale Club on May 18th, 2009.
In honor of the occasion, Crocker Coulson, President of CCG Investor
Relations, will preside over the Closing Bell. He will be joined by
representatives from Chinese companies.
Who:
Some of the participating companies include:
* Zhongpin Inc. (NasdaqGS:HOGS - News)
* Yuhe International Inc (OTC BB:YUII.OB - News)
* Silicon Motion (NasdaqGS:SIMO - News)
* Puda Coal, Inc (OTC BB:PUDC.OB - News)
* Jiangbo Pharmaceuticals, Inc. (OTC BB:JGBO.OB - News)
* Hong Kong Highpower Technology, Inc. (AMEX:HPJ - News)
* Dragon Pharmaceutical Inc. (OTC BB:DRUG.OB - News)
* China Yida Holding (OTC BB:CYID.OB - News)
* China Wind Systems, Inc. (OTC BB:CWSI.OB - News)
* China Transinfo Technology (NasdaqCM:CTFO - News)
* China Nutrifruit Group Limited (OTC BB:CNGL.OB - News)
* China Medicine Corporation (OTC BB:CHME.OB - News)
* China Biologic Products, Inc. (OTC BB:CBPO.OB - News)
* China-Biotics, Inc. (NasdaqGM:CHBT - News)
* ATA, Inc. (NasdaqGM:ATAI - News)
* Asia Biochem Group Corp. (CDNX:ABC.V - News)
* American Lorain Corporation (OTC BB:ALRC.OB - News)
Where:
NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio
When:
Monday, May 18th, 2009 at 3:45 p.m. to 4:00 p.m. ET
Contacts:
Mabel Zhang
CCG Investor Relations
(310) 954-1353 (office)
Mabel.zhang@ccgir.com
NASDAQ MarketSite:
Robert Madden
(646) 441-5045 (office)
Robert.Madden@NASDAQOMX.com
http://finance.yahoo.com/news/China-Rising-Investment-pz-15258116.html
http://www.sec.gov/Archives/edgar/data/1091164/...483/v149760_10q.htm
In November 2008, the Board of the Directors of the Company authorized a share buyback program to purchase the Company’s common stock in the open market with a $2,000,000 limitation.
As of March 31, 2009, the Company has not purchased any shares in the open market.
Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal Year 2009
http://www.finanznachrichten.de/...er-of-its-fiscal-year-2009-008.htm
LAIYANG, China, May 18 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (BULLETIN BOARD: JGBO) ('Jiangbo' or the 'Company'), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced its financial results for the third quarter ended March 31, 2009 of its fiscal year 2009.
Third Quarter of Fiscal Year 2009 Highlights
-- Total revenue, which reflects newly associated expense restructuring, was $25.7 million, compared to $28.1 million in the corresponding quarter of 2008
-- Gross profit was $18.9 million, compared to $21.8 million in the corresponding quarter of 2008, and gross margin was 73.4% compared to 77.4% in the corresponding quarter of 2008
-- Operating income was $13.3 million, a 53.6% increase from $8.7 million for the three months ended March 31, 2008
-- Net income was $8.9 million, or $0.44 per fully diluted share, up from $4.5 million, or $0.46 per fully diluted share, for the three months ended March 31, 2008
-- Non-GAAP adjusted net income was $10.0 million, or $0.97 per weighted average share for the three months ended March 31, 2009, up 66.5% from non-GAAP adjusted net income of $6.0 million, or $0.61 per weighted average number of shares, for the quarter ended March 31, 2008
-- Acquired Shandong Hongrui Pharmaceutical Factory ("Hongrui") for approximately $11.2 million consisting of RMB58.6 million in cash (approximately $8.6 million) and 643,651 shares of Jiangbo's common stock amounting to approximately $2.6 million
-- Obtained the legal rights to manufacture and distribute Hongrui's 22 Traditional Chinese Medicines
-- Restructured its sales network to distribute products through 28 large regional distributors
-- Changed the corporate name from Genesis Pharmaceuticals Enterprises, (News) Inc. to 'Jiangbo Pharmaceuticals, Inc.' and its stock symbol from 'GNPH' to 'JGBO'.
-- Launched a new website: http://www.jiangbopharma.com/
...(weiter siehe LINK)
In reply to: None Post # of 5662
Highlights from C.C. so far-working on SFDA approval for the 4 new products still, Sarbannes Oxley compliance-applying for NASDAQ listing this summer, 5 Hongrui products launched, 6 more up for launch in next 12 months, looking for acquisitions-specifically strategic-companies with exclusive proprietary products to provide business advantage. Full renovation of Hungrui factory planned or underway-not sure-50 million RMNB cost I think. Great results-bright future!
Video with Elsa Sung of Jiangbo:
http://www.thestreet.com/video/index.html#23797888001
HAHA...lasst uns erstmal uplisten...mein Ziel...never sell...hehe
Hab mal den jiangbo betreffenden Text rauskopiert
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38085883
LAIYANG, China, April 22, 2009 /PRNewswire-Asia-FirstCall via COMTEX/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it began marketing and selling three Traditional Chinese Medicines ("TCMs"). These TCMs are Yi Mu Cao Gao (a motherwort herb electuary sticky syrup), Gan Mao Zhi Ke Ke Li (an antipyretic and antitussive granule), and Kang Gu Sui Yan Pian (an osteomyelitis treatment tablet).